[Linezolid--novel antibiotic for the treatment of gram-positive bacterial infections].
Linezolid, the first of a new class of antibiotics, the oxazolidinones, is approved for the treatment of Gram-positive bacterial infections, including resistant strains. Linezolid possesses bacteriostatic activity against both antibiotic-susceptible and resistant strains of staphylococci, enterococci and streptococci of relevance to human infection. Clinical trials have confirmed its effectiveness in the treatment of serious infections of skin and soft tissue and the lower respiratory tract. Linezolid has also provided improved outcomes in the treatment of serious vancomycin-resistant entrococci (VRE) and methicillin-resistant Staphylococcus aureus (MRSA) infections. It is well absorbed with high bioavailability after oral administration and generally well tolerated.
Jankowski
Andrzej
A
Z Katedry i Zakładu Farmacji Stosowanej w Sosnowcu, Slaskiej Akademii Medycznej w Katowicach.
Stefanik
Wioletta
W
D000081:Acetamides / Q000493:pharmacokinetics / Q000494:pharmacology*; D000890:Anti-Infective Agents / Q000493:pharmacokinetics / Q000494:pharmacology*; D001170:Arthritis, Infectious / Q000188:drug therapy; D001850:Bone Diseases, Infectious / Q000188:drug therapy; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D006094:Gram-Positive Bacteria / Q000187:drug effects* / Q000378:metabolism*; D016908:Gram-Positive Bacterial Infections / Q000188:drug therapy*; D006801:Humans; D000069349:Linezolid; D008826:Microbial Sensitivity Tests; D023303:Oxazolidinones / Q000493:pharmacokinetics / Q000494:pharmacology*; D011014:Pneumonia / Q000188:drug therapy; D016459:Prosthesis-Related Infections / Q000188:drug therapy* / Q000378:metabolism
D000081:Acetamides; D000890:Anti-Infective Agents; D023303:Oxazolidinones; D000069349:Linezolid